Prescription Drug Addiction in the US Compared to the Rest of the World

The American Epidemic Hidden in Plain Sight

 

Prescription drug addiction is a fast-growing global problem – one that has no respect for boundaries of geography, creed, or culture. It spreads diseases, reinforces crime, and lowers the productivity of human resources through its negative influence on users.

Even worse, we are often reminded, in a most tragic way, of the deadly consequences drug use can bring. Every year, prescription drug abuse kills more people than car accidents, per a Drugwatch report. A TheGuardian piece states that more Americans died from overdoses in 2015 than car crashes and gun deaths combined.

But how does prescription drug addiction in the US compare to that of other nations?

The US Vs. Rest of the World

It’s no secret that prescription drug use is a pervasive problem of major American concern. Data from the 2016 National Study on Drug Use and Health show that an estimated 28.6 million US citizens who are 12 years or older used illicit drugs in the period leading to the study.

A further 54 million Americans who are at least 12 years of age have used prescription drugs for nonmedical reasons during their lifetime, according to the Talbott Recovery.

America makes up about 5% of the world’s population – but accounts for approximately 27 percent of the world’s drug overdose deaths, according to Vox. The culprit? Prescription opioids like Oxycontin, tramadol, methadone, morphine, fentanyl or Vicodin.

These drugs are often used to ease chronic and acute pains, such as those associated with cancer. However, what was initially intended for good ended up paving the way for a national health crisis when it became severely abused.

In 2015, an estimated 8.5 million (3%) Americans misused opioid painkillers, while about 2.5 million were addicted to either heroin or painkillers. Over 33,000 people died after overdosing on illicit drugs.

In contrast, of 507 million people, only around 1.3 million (0.4%) were considered high-risk opioid users in the EU, per the Vox report. Opioid overdose deaths were put at 6,800. In 2015, about 62,000 died of drug overdoses in Asia, while in America alone, around 52,400 citizens were lost to drug overdoses that same year.

Data show that Americans consume about 30 percent of the global opioid supply. In addition, Americans consume the vast majority of the world’s opioids, including 99% of the world’s hydrocodone.

Major Culprits

Research conducted by scientists at Mayo Clinic and Olmsted Medical Center found that almost 70% of the citizens of the United States are on at least one prescription drug, while more than half receive at least two prescription drugs. The most commonly prescribed medications were found to include:

Used for treating bacteria that cause illness, antibiotics are the most widely prescribed drugs. This also makes them one of the most abused. Antibiotics abuse often leads to superbugs, a form of bacteria that are resistant to many – if not all types of antibiotics. Some of the most commonly prescribed synthetic antibiotics include Ciproflaxin (Cipro), Penicillin, Levofloxacin (Levaquin), Moxifloxacin (Avelox), etc.

Opioids are synthetic prescription painkillers, although this definition often includes heroin. Examples of synthetic analgesics include Vicodin, OxyContin, Duragesic, Opana, and Dilaudid.

Studies show that antidepressants increase the risk of suicidal thinking and may lead to congenital disabilities if taken by pregnant women. Other side effects of these drugs include upset stomach, headaches, and nausea. Citalopram (Celexa), Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine (Paxil), etc., are some examples of synthetic antidepressants.

 

 

Checkout Unique Finance and get a bonus from me.

FIRST FOODS GROUP SUBSIDIARY ‘HOLY CACAO’ TO SWEETEN THE CANNABIS MARKET

 

 

 

        Read About the amazing Developments in Edible Cannabis Chocolates

 

       World-famous chocolatier, Oded Brenner, visionary behind Holy Cacao 

 

The Chocolate Vision for Cannabis Edibles

A young public company wants to grab share in the ever-growing cannabis market. First Foods Group, Inc. (“OTCQB: “FIFG), has taken an unconventional, but creatively successful route toward penetrating the exploding legal cannabis market expected to reach over $50 billion by 2025.

The Company’s recently incorporated subsidiary, Holy Cacao, is gearing up to market premium chocolate edibles that have been created and packaged by Oded Brenner, founder of “Max Brenner, Chocolate by the Bald Man.”  Brenner’s design, marketing and culinary artistry were behind the global success of the Max Brenner brand.

‘Merchant Advances’ Advancing Company’s Cannabis Strategy

So how is First Foods able to pile on cash so fast for its cannabis coup, while still maintaining just 16 million shares outstanding and zero debt? The answer is the Company has developed a powerful, fast growing revenue stream that already has produced impressive returns for its shareholders (www.FirstFoodsGroup.com)

In October, FIFG began investing in a variety of merchant services, whereby it makes short-term cash advances to businesses in return for an agreed-upon amount of future sales, paid by the businesses in small, regular daily payments. In just one month the Company has received a whopping 24.5% return on its investments according to CEO Harold Kestenbaum in a November 22nd Press Release.

 

Start-up Capital Now in Place

CFO Mark Keeley, who heads the new First Foods Funding Division, said he has already obtained all the start-up capital needed that will enable the company to speed its plans to target the burgeoning legal marijuana industry with its unique Holy Cacao product line.

The company said acclaimed cannabis expert Rob Hunt is leading Holy Cacao’s efforts to gain traction in the legalized states. Hunt is considered one of the most knowledgeable, connected and sought-after experts in the cannabis industry. He has already introduced the brand to some of the largest players in the edibles sector, all of whom are showing interest in signing on with Holy Cacao’s aggressive growth agenda. Hunt is now negotiating manufacturing and distribution deals, anticipating product launch in first quarter, 2018.

Remarkably Self-funded

To date, First Foods Group has been entirely self-funded by the Company’s Board of Directors, a rarity for a young public entity. This has kept the number of outstanding shares at the same 16 million that was in place at the time of capitalization, with virtually no short term, long term, or convertible debt anywhere to be seen. This is a formula that experienced investors rarely overlook, as it shows that the Board has its shareholders’ long term well-being as its primary focus.

TransMedia Group Retained to Roll Out PR Campaign

First Foods Group has retained the award-winning international public relations firm TransMedia Group (www.transmediagroup.com) to publicize its progress in readying “Holy Cacao” for entry into the growing cannabis market globally.  The PR firm has a long and distinguished track record in serving clients worldwide since 1981.  TransMedia Group has helped to make many public companies and their products successful from AT&T to Rexall Sundown, whose founder Carl DeSantis credits TransMedia for the awesome success of his company, which he sold for $1.6 billion.

 

 

 

 

 

Checkout Unique Finance and get a bonus from me.

FIRST FOODS GROUP SUBSIDIARY ‘HOLY CACAO’ TO SWEETEN THE CANNABIS MARKET

 

 

 

        Read About the amazing Developments in Edible Cannabis Chocolates

 

       World-famous chocolatier, Oded Brenner, visionary behind Holy Cacao 

 

The Chocolate Vision for Cannabis Edibles

A young public company, First Foods Group, Inc. (“OTCQB: “FIFG), has taken an unconventional, but creatively successful route toward penetrating the exploding legal cannabis market expected to reach over $50 billion by 2025.

The Company’s recently incorporated subsidiary, Holy Cacao, is gearing up to market premium chocolate edibles that have been created and packaged by Oded Brenner, founder of “Max Brenner, Chocolate by the Bald Man.”  Brenner’s design, marketing and culinary artistry were behind the global success of the Max Brenner brand.

‘Merchant Advances’ Advancing Company’s Cannabis Strategy

So how is First Foods able to pile on cash so fast for its cannabis coup, while still maintaining just 16 million shares outstanding and zero debt? The answer is the Company has developed a powerful, fast growing revenue stream that already has produced impressive returns for its shareholders (www.FirstFoodsGroup.com)

In October, FIFG began investing in a variety of merchant services, whereby it makes short-term cash advances to businesses in return for an agreed-upon amount of future sales, paid by the businesses in small, regular daily payments. In just one month the Company has received a whopping 24.5% return on its investments according to CEO Harold Kestenbaum in a November 22nd Press Release.

 

Start-up Capital Now in Place

CFO Mark Keeley, who heads the new First Foods Funding Division, said he has already obtained all the start-up capital needed that will enable the company to speed its plans to target the burgeoning legal marijuana industry with its unique Holy Cacao product line.

The company said acclaimed cannabis expert Rob Hunt is leading Holy Cacao’s efforts to gain traction in the legalized states. Hunt is considered one of the most knowledgeable, connected and sought-after experts in the cannabis industry. He has already introduced the brand to some of the largest players in the edibles sector, all of whom are showing interest in signing on with Holy Cacao’s aggressive growth agenda. Hunt is now negotiating manufacturing and distribution deals, anticipating product launch in first quarter, 2018.

Remarkably Self-funded

To date, First Foods Group has been entirely self-funded by the Company’s Board of Directors, a rarity for a young public entity. This has kept the number of outstanding shares at the same 16 million that was in place at the time of capitalization, with virtually no short term, long term, or convertible debt anywhere to be seen. This is a formula that experienced investors rarely overlook, as it shows that the Board has its shareholders’ long term well-being as its primary focus.

 

TransMedia Group Retained to Roll Out PR Campaign

First Foods Group has retained the award-winning international public relations firm TransMedia Group (www.transmediagroup.com) to publicize its progress in readying “Holy Cacao” for entry into the growing cannabis market globally.  The PR firm has a long and distinguished track record in serving clients worldwide since 1981.  TransMedia Group has helped to make many public companies and their products successful from AT&T to Rexall Sundown, whose founder Carl DeSantis credits TransMedia for the awesome success of his company, which he sold for $1.6 billion.

 

 

 

 

 

Checkout Unique Finance and get a bonus from me.

Med-X Inc. Resumes Equity rowdfunding

Medical cannabis-focused Med-X, Inc. has resumed its equity crowdfunding campaign through StartEngine.com in a bid to raise $14.1 million through a minimum $420 per 700 shares.The manufacturer of non-toxic insecticide and pesticide for marijuana cultivators and publisher of The Marijuana Times relaunched the campaign on Sept. 28, 2017 following the lifting of its Securities and Exchange Commission temporary suspension arising from a late filing last year.“We have been qualified by the SEC and believe we are in full compliance to resume our Regulation A+ crowdfunding efforts once again,” said Chief Operations Officer Matthew Mills.

 

Med-X Inc. became the first cannabis company to launch a Regulation A+ equity crowdfunding campaign provided in the 2012 JOBS Act. It is also the first company involved with cannabis that StartEngine allowed to raise capital through its platform.”They let us jump on their platform, as we agreed not pursue handling the plant until it’s legal to do so,” said Mills. Mills said FundAmerica is handling the campaign that has raised under $1 million so far.The management team has been diligently working on its business model and continues positioning the company in accordance with its initial plan of operations.”The primary focus will be on the Nature-Cide product line for natural pest control in cannabis cultivation, along with the continued development of the popular online cannabis industry publication, The Marijuana Times,” according to Mills.

 

Nature-Cide

With cities in California and other states legalizing marijuana cultivation and manufacturing, the number of legal indoor pot farms and manufacturing sites for edible products is expected to increase driving demand for improving the quality and safety of local marijuana.Med-X has begun supplying Nature-Cide Pest Management and All-Purpose formulations to the cannabis agricultural and provisioning industries. It is also preparing for distribution its newly developed Nature-Cide insecticidal soil product for all types cultivators. The formulations are a proprietary all-natural essential oil insecticide/miticide/nematicide that repels and kill a wide variety of pests commonly known to damage cannabis crops. Nature-Cide products are listed on the “Approved for use in the Cultivation of Marijuana” by the Colorado, Washington and Oregon state Agriculture Departments. The listing is supported by Med-X’s 18-Month Nature-Cide Integrated Pest Management (IPM) for Cannabis Cultivation Report released in March. “The 18-month report began in 2015 shortly after realizing that the Nature-Cide pesticide products were being recognized by multiple state agricultural departments as a product that is approved for use in medical and recreational marijuana cultivation,” said Mills.

 

Growth advantage

 The legal cannabis industry grew 30 percent in 2016 in North America alone to reach to $6.7 billion because of high growth prospects in the U.S. and Canada, data from Arcview Market Research showed. Arcview is projecting a 25 percent annual growth rate with sales in North American reaching $20.2 billion by 2021. Med-X is in great position to take advantage of the opportunities in the legal cannabis space.While primarily in the business of research and development of commercial medicinal applications of cannabis, Med-X Inc. plans to address other needs required to support the fast-paced emerging cannabis industry, including compound identification and extraction from cannabis oils, along with pharmacy automation beginning with cannabis products and eventually for various pharmaceuticals.According to its SEC filings, Med-X Inc. plans to cultivate and sell high-quality cannabis for the consumer and commercial markets in areas where it is legal and when they are fully licensed to do so. “Due to our management’s hands-on background in the fields of medicine, large-scale cultivation, commercial pest management as well as operations in internet-based wholesale and retail outlets, we feel we have a tremendous advantage, and can use that skill set to climb into a growth position more rapidly than most,” said Mills.

 

About Med-X, Inc.

 Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced emerging cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compound for the present medical industry demand. The company’s digital magazine, The Marijuana Times, publishes quality media content for the medical cannabis community to generate revenue from advertisers as well as sell industry related merchandise to consumers. The company is ready to bring various products to market in the cannabis, agricultural and ancillary services industries through manufacturing partnerships. For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.comor call 818-349-2870.

 

Checkout Unique Finance and get a bonus from me.

Med-X Inc. Resumes Equity Crowdfunding

 

Medical cannabis-focused Med-X, Inc. has resumed its equity crowdfunding campaign through StartEngine.com in a bid to raise $14.1 million through a minimum $420 per 700 shares.

The manufacturer of non-toxic insecticide and pesticide for marijuana cultivators and publisher of The Marijuana Times relaunched the campaign on Sept. 28, 2017 following the lifting of its Securities and Exchange Commission temporary suspension arising from a late filing last year.

“We have been qualified by the SEC and believe we are in full compliance to resume our Regulation A+ crowdfunding efforts once again,” said Chief Operations Officer Matthew Mills.

 

Med-X Inc. became the first cannabis company to launch a Regulation A+ equity crowdfunding campaign provided in the 2012 JOBS Act. It is also the first company involved with cannabis that StartEngine allowed to raise capital through its platform.

“They let us jump on their platform, as we agreed not pursue handling the plant until it’s legal to do so,” said Mills.

Mills said FundAmerica is handling the campaign that has raised under $1 million so far.The management team has been diligently working on its business model and continues positioning the company in accordance with its initial plan of operations.

“The primary focus will be on the Nature-Cide product line for natural pest control in cannabis cultivation, along with the continued development of the popular online cannabis industry publication, The Marijuana Times,” according to Mills.

 

Nature-Cide

With cities in California and other states legalizing marijuana cultivation and manufacturing, the number of legal indoor pot farms and manufacturing sites for edible products is expected to increase driving demand for improving the quality and safety of local marijuana.

Med-X has begun supplying Nature-Cide Pest Management and All-Purpose formulations to the cannabis agricultural and provisioning industries. It is also preparing for distribution its newly developed Nature-Cide insecticidal soil product for all types cultivators. The formulations are a proprietary all-natural essential oil insecticide/miticide/nematicide that repels and kill a wide variety of pests commonly known to damage cannabis crops.

Nature-Cide products are listed on the “Approved for use in the Cultivation of Marijuana” by the Colorado, Washington and Oregon state Agriculture Departments. The listing is supported by Med-X’s 18-Month Nature-Cide Integrated Pest Management (IPM) for Cannabis Cultivation Report released in March.

“The 18-month report began in 2015 shortly after realizing that the Nature-Cide pesticide products were being recognized by multiple state agricultural departments as a product that is approved for use in medical and recreational marijuana cultivation,” said Mills.

 

Growth advantage

 The legal cannabis industry grew 30 percent in 2016 in North America alone to reach to $6.7 billion because of high growth prospects in the U.S. and Canada, data from Arcview Market Research showed. Arcview is projecting a 25 percent annual growth rate with sales in North American reaching $20.2 billion by 2021.

Med-X is in great position to take advantage of the opportunities in the legal cannabis space.

While primarily in the business of research and development of commercial medicinal applications of cannabis, Med-X Inc. plans to address other needs required to support the fast-paced emerging cannabis industry, including compound identification and extraction from cannabis oils, along with pharmacy automation beginning with cannabis products and eventually for various pharmaceuticals.

According to its SEC filings, Med-X Inc. plans to cultivate and sell high-quality cannabis for the consumer and commercial markets in areas where it is legal and when they are fully licensed to do so.

“Due to our management’s hands-on background in the fields of medicine, large-scale cultivation, commercial pest management as well as operations in internet-based wholesale and retail outlets, we feel we have a tremendous advantage, and can use that skill set to climb into a growth position more rapidly than most,” said Mills.

 

About Med-X, Inc.

 Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced emerging cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compound for the present medical industry demand. The company’s digital magazine, The Marijuana Times, publishes quality media content for the medical cannabis community to generate revenue from advertisers as well as sell industry related merchandise to consumers. The company is ready to bring various products to market in the cannabis, agricultural and ancillary services industries through manufacturing partnerships. For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.comor call 818-349-2870.

 

Checkout Unique Finance and get a bonus from me.